Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma

Hepatology Research

Volumn 43, Issue 9, 2013, Pages 942-949

  Seko, Yuya ^a   Ikeda, Kenji ^a   Kawamura, Yusuke ^a   Fukushima, Taito ^a   Hara, Tasuku ^a   Sezaki, Hitomi ^a   Hosaka, Tetsuya ^a   Akuta, Norio ^a   Suzuki, Fumitaka ^a   Kobayashi, Masahiro ^a   Suzuki, Yoshiyuki ^a   Saitoh, Satoshi ^a   Arase, Yasuji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Hepatocellular carcinoma; Miriplatin; Transcatheter arterial chemoembolization

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; BILIRUBIN; CREATINE; MIRIPLATIN; PROTHROMBIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ROOM TEMPERATURE;

EID: 84883539639     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12041     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 2009; 44 (Suppl): 102-107.
3. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148: 397-401.
4. Lin DY, Liaw YF, Lee TY, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Gastroenterology 1988; 94: 453-456.
5. Ikeda K, Kumada H, Saitoh S, Arase Y, Chayama K. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. Cancer 1991; 68: 2150-2154.
6. Llovet JM, Real MI, Montana X etal.; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739.
7. Lo CM, Ngan H, Tso WK etal. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171.
8. Camma C, Schepis F, Orlando A etal. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224: 47-54.
9. Ikeda M, Maeda S, Shibata J etal. Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology 2004; 66: 24-31.
10. Takayasu K, Arii S, Ikai I etal.; Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-469.
11. Arii S, Sata M, Sakamoto M etal. Management of hepatocellular carcinoma: report of consensus meeting in the 45th annual meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010; 40: 667-685.
12. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127 (5 Suppl 1): S179-S188.
13. Maeda M, Uchida NA, Sasaki T. Liposoluble platinum (II) complexes with antitumor activity. Jpn J Cancer Res 1986; 77: 523-525.
14. Kishimoto S, Ohtani A, Fukuda H, Fukushima S, Takeuchi Y. Relation between intracellular accumulation and cytotoxic activity of cis-[((1R, 2R)-1, 2-cyclohexanediamine- N, N')bis(myristato)]platinum(II) suspended in Lipiodol. Biol Pharm Bull 2003; 26: 683-686.
15. Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted in nude rats. Cancer Sci 2009; 100: 189-194.
16. Hanada M, Baba A, Tsutsumishita Y etal. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol 2009; 64: 473-483.
17. Fujiyama S, Shibata J, Maeda S etal. Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodol. Br J Cancer 2003; 89: 1614-1619.
18. Okusaka T, Okada S, Nakanishi T, Fujiyama S, Kubo Y. Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. Invest New Drugs 2004; 22: 169-176.
19. Imai N, Ikeda K, Kawamura Y etal. Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Jpn J Clin Oncol 2012; 42: 175-182.
20. Imai N, Ikeda K, Seko Y etal. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma. Oncology 2011; 80: 188-194.
21. Imai Y, Chikayama T, Nakazawa M etal. Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Gastroenterol 2011 [Epub ahead of print].
22. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
23. Marelli L, Stigliano R, Triantos C etal. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25.
24. Kamada K, Nakanishi T, Kitamoto M etal. Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol 2001; 12: 847-854.
25. Kawamura Y, Ikeda K, Hirakawa M etal. Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin. Hepatol Res 2009; 39: 346-354.
26. Imai N, Ikeda K, Seko Y etal. Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and chronic renal failure. Nihon Shokakibyo Gakkai Zasshi 2011; 108: 1872-1878.
27. Kishimoto S, Miyazawa K, Terakawa Y etal. Cytotoxicity of cis-[((1R, 2R)-1, 2-cyclohexanediamine-N, N')bis(myristato)]-platinum (II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line. Jpn J Cancer Res 2000; 91: 1326-1332.
28. Miyayama S, Yamashiro M, Shibata Y etal. Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma. Jpn J Radiol 2012; 30: 263-270.
29. Shim JH, Kim KM, Lee YJ etal. Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection. Ann Surg Oncol 2010; 17: 869-877.